亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Effectiveness of Anti-CD20 B cells depleting therapy versus conventional treatment in severe Anti-N-methyl-d-aspartate receptor encephalitis: A real-world multi-center prospective cohort study

作者
Baojie Wang,Yao Xiao,Yufeng Chu,Chunjuan Wang,Hao Sun,Teng Huang,Danqing Qin,Xuetao Cao,Shuai Guo,Haotian Zhao,Xiumin Zhao,Shougang Guo
出处
期刊:Neurotherapeutics [Springer Science+Business Media]
卷期号:22 (6): e00766-e00766
标识
DOI:10.1016/j.neurot.2025.e00766
摘要

Approximately 25 ​%-40 ​% of anti-N-methyl-d-aspartate receptor encephalitis (NMDARE) patients develop refractory disease with prolonged neurological deficits. We aim to evaluate the efficacy of B cell depletion therapy (BCDT) via CD20 antibodies versus conventional first-line immunotherapy only (intravenous methylprednisolone for 5 days, 0.4 ​g/kg intravenous immunoglobulin for 5 days, and ≥4 consecutive plasma exchange treatments, non-BCDT group) in treatment of severe NMDARE in the real-world setting. From multicenter cohort of severe NMDARE, 108 patients (ofatumumab group 36; rituxixmab group 36; non-BCDT group 36) were prospectively reviewed. The primary end point was the proportion of patients to achieving good outcomes (modified Rankin Scale scores ≤2) at 3 months. Secondary end points included longitudinal outcomes assessed by mRS scores and Clinical Assessment Scale in Autoimmune Encephalitis (CASE) scores, cognitive function and adverse events (AEs). BCDT demonstrated a higher frequency of mRS scores ≤2 compared to non-BCDT at 3 months (ofatumumab 63.9 ​% vs. non-BCDT 36.1 ​%, p ​< ​0.001; rituximab 55.6 ​% vs. non-BCDT 36.1 ​%, p ​= ​0.007, respectively). Ofatumuamb showed superior therapeutic response at 1 month compared to both rituximab-treated patients (mean CASE score: 5.89 vs 7.91, p ​= ​0.025) and non-BCDT treated patients (mean CASE score: 5.89 vs 9.97, p ​< ​0.0001). All groups improved over 12 months, with significantly higher complete remission rates in BCDT groups (70.8 ​%-75 ​% vs. 55.6 ​%, p ​< ​0.05). Five of 33 patients (15.2 ​%) experienced persistent mild cognitive impairment. AEs were mild-to moderate in severity. We calculated the probability of relapse-free as ofatumumab and rituximab reduced risk of disease relapses compared to non-BCDT (ofatumumab vs. non-BCDT: HR, 0.193; 95 ​% CI, 0.062-0.6; p ​= ​0.007; rituximab vs. non-BCDT: HR, 0.265; 95 ​% CI, 0.089-0.787; p ​= ​0.029). Therefore, we suggest that BCDT effectively promoted neurological recovery, and reduced relapse risk with favorable safety, while ofatumumab demonstrated superior efficacy in controlling early disease severity.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
风落完成签到 ,获得积分10
2秒前
前方的菜鸟完成签到 ,获得积分10
3秒前
molihuakai的应助被是绿子吖采纳,获得10
3秒前
11秒前
amiee发布了新的文献求助10
14秒前
乐观寻芹完成签到,获得积分10
22秒前
27秒前
清爽的孤丝完成签到,获得积分10
30秒前
32秒前
儒雅的新儿完成签到,获得积分10
43秒前
星野的应助被吴金菊采纳,获得10
44秒前
汉堡包的应助被萧雨墨采纳,获得10
48秒前
50秒前
海洋球完成签到,获得积分10
50秒前
56秒前
Hyp完成签到 ,获得积分10
57秒前
58秒前
59秒前
萧雨墨发布了新的文献求助10
1分钟前
yuyu完成签到,获得积分10
1分钟前
Eric的应助被Bugs采纳,获得10
1分钟前
乐乐的应助被Celia采纳,获得10
1分钟前
fantasy的应助被科研通管家采纳,获得10
1分钟前
fantasy的应助被科研通管家采纳,获得10
1分钟前
1分钟前
Maestro_S的应助被科研通管家采纳,获得10
1分钟前
fantasy的应助被科研通管家采纳,获得10
1分钟前
叶云夕完成签到,获得积分10
1分钟前
尽落完成签到 ,获得积分10
1分钟前
萧雨墨发布了新的文献求助10
1分钟前
奋斗不二完成签到,获得积分10
1分钟前
王露完成签到 ,获得积分10
1分钟前
星辰大海的应助被dart1023采纳,获得10
1分钟前
刘研完成签到,获得积分10
1分钟前
刘研发布了新的文献求助10
1分钟前
1分钟前
一杯茶具完成签到 ,获得积分10
2分钟前
2分钟前
2分钟前
luyiyi发布了新的文献求助10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190075
求助须知:如何正确求助?哪些是违规求助? 9577208
关于积分的说明 21851965
捐赠科研通 7788198
什么是DOI,文献DOI怎么找? 3436234
关于科研通互助平台的介绍 2559936
邀请新用户注册赠送积分活动 2482810